According to the Zhituo Finance APP, Chengdu Kanghong Pharmaceutical Group (002773.SZ) announced that the company recently received the "Pharmaceutical Registration Certificate" (Certificate Number: 2024S02804) issued by the National Medical Products Administration, approving the registration of sodium hyaluronate eye drops. Indications: Corneal and conjunctival epithelial damage accompanying the following diseases: Sjögren's syndrome, Stevens-Johnson syndrome, dry eye syndrome, and other endogenous diseases; exogenous diseases following surgery, medication, trauma, and contact lens wear.

The approval for the sodium hyaluronate eye drops to be sold enriches the company's product pipeline in the ophthalmology field.